CBAY

Cymabay Therapeutics
CBAY

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings
 

About: CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Employees: 101

Healthcare Drug Manufacturers - General
Price charts implemented using Lightweight Charts™